{"DataElement":{"publicId":"6944815","version":"1","preferredName":"Target Lesion irRECIST Type","preferredDefinition":"The disease response in a target lesion using the Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST).","longName":"RSTGIRRSP","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"6941682","version":"1","preferredName":"Disease Response Domain Target Lesion Disease Response","preferredDefinition":"A domain for disease response evaluations._An object fixed as a goal or point of examination; something to point at; a destination._A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part._The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","longName":"6608777v1.0:6941680v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6608777","version":"1","preferredName":"Disease Response Domain","preferredDefinition":"A domain for disease response evaluations.","longName":"C107097","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease Response Domain","conceptCode":"C107097","definition":"A domain for disease response evaluations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F6DD03A-0CB9-71AE-E053-F662850AB42C","latestVersionIndicator":"Yes","beginDate":"2019-01-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-01-14","modifiedBy":"ONEDATA","dateModified":"2019-01-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6941680","version":"1","preferredName":"Target Lesion Disease Response","preferredDefinition":"An object fixed as a goal or point of examination; something to point at; a destination.:A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.:The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","longName":"C25702:C3824:C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Target","conceptCode":"C25702","definition":"An object fixed as a goal or point of examination; something to point at; a destination.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Lesion","conceptCode":"C3824","definition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"92C1BE35-8E53-5FCF-E053-F662850A302C","latestVersionIndicator":"Yes","beginDate":"2019-09-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-09-17","modifiedBy":"ONEDATA","dateModified":"2019-09-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435019","version":"1","preferredName":"Conceptual Entity","preferredDefinition":"An organizational header for concepts representing mostly abstract entities.","longName":"C20181","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D8-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"92C1BE35-8E64-5FCF-E053-F662850A302C","latestVersionIndicator":"Yes","beginDate":"2019-09-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-09-17","modifiedBy":"COOPERM","dateModified":"2020-06-04","changeDescription":"Created for CDISC aligned NCI CRF standards task. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6002994","version":"2","preferredName":"irRECIST Target Type","preferredDefinition":"A set of criteria for capturing the unidimensional measurements which are used to assess the effect of immunotherapeutic agents on solid tumors. These criteria are based on elements of the Immune-Related Response Criteria (irRC) and Immune-related RECIST (irRECIST)._An object fixed as a goal or point of examination; something to point at; a destination._Something distinguishable as an identifiable class based on common qualities.","longName":"6002994v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"4","maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"irCR","valueDescription":"irCR","ValueMeaning":{"publicId":"6001372","version":"1","preferredName":"irCR","longName":"6001372","preferredDefinition":"A complete disappearance of  all measurable and non-measurable lesions. Lymph nodes must decrease to less than 10 mm in short axis. Confirmation of response is not mandatory.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"irRECIST Complete Response","conceptCode":"C140316","definition":"A complete disappearance of all measurable and non-measurable lesions. Lymph nodes must decrease to < 10 mm in short axis. Confirmation of response is not mandatory.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B46FAD0-75C8-3F97-E053-F662850A260F","latestVersionIndicator":"Yes","beginDate":"2017-10-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-11","modifiedBy":"KUMMEROA","dateModified":"2022-08-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6419F027-ADA8-089A-E053-F662850A4BDA","beginDate":"2017-10-12","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-01-31","modifiedBy":"ONEDATA","dateModified":"2018-01-31","deletedIndicator":"No"},{"value":"irPD","valueDescription":"irPD","ValueMeaning":{"publicId":"6001374","version":"1","preferredName":"irPD","longName":"6001374","preferredDefinition":"A minimum 20% increase and minimum 5 mm absolute increase in total measured tumor burden compared to nadir, or irPD for non-target or new non-measurable lesions. Confirmation of progression is recommended minimum 4 weeks after the first irPD assessment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"irRECIST Progressive Disease","conceptCode":"C140319","definition":"A minimum 20% increase and minimum 5 mm absolute increase in total measured tumor burden compared to nadir, or irPD for non-target or new non-measurable lesions. Confirmation of progression is recommended minimum 4 weeks after the first irPD assessment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B46FAD0-7612-3F97-E053-F662850A260F","latestVersionIndicator":"Yes","beginDate":"2017-10-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-11","modifiedBy":"KUMMEROA","dateModified":"2022-08-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6419F027-ADB2-089A-E053-F662850A4BDA","beginDate":"2017-10-12","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-01-31","modifiedBy":"ONEDATA","dateModified":"2018-01-31","deletedIndicator":"No"},{"value":"irPR","valueDescription":"irPR","ValueMeaning":{"publicId":"6001373","version":"1","preferredName":"irPR","longName":"6001373","preferredDefinition":"A decrease of greater than or equal to 30% in TMTB relative to baseline, non-target lesions are irNN, and no unequivocal progression of new non-measurable lesions","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"irRECIST Partial Response","conceptCode":"C140315","definition":"A decrease of 30% or more in TMTB relative to baseline, non-target lesions are irNN, and no unequivocal progression of new non-measurable lesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B46FAD0-75ED-3F97-E053-F662850A260F","latestVersionIndicator":"Yes","beginDate":"2017-10-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-11","modifiedBy":"KUMMEROA","dateModified":"2022-08-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6419F027-ADBC-089A-E053-F662850A4BDA","beginDate":"2017-10-12","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-01-31","modifiedBy":"ONEDATA","dateModified":"2018-01-31","deletedIndicator":"No"},{"value":"irSD","valueDescription":"irSD","ValueMeaning":{"publicId":"6001375","version":"1","preferredName":"irSD","longName":"6001375","preferredDefinition":"A failure to meet criteria for irCR or irPR in the absence of irPD.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"irRECIST Stable Disease","conceptCode":"C140317","definition":"A failure to meet criteria for irCR or irPR in the absence of irPD.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B46FAD0-7637-3F97-E053-F662850A260F","latestVersionIndicator":"Yes","beginDate":"2017-10-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-11","modifiedBy":"KUMMEROA","dateModified":"2022-08-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6419F027-ADC6-089A-E053-F662850A4BDA","beginDate":"2017-10-12","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-01-31","modifiedBy":"ONEDATA","dateModified":"2018-01-31","deletedIndicator":"No"},{"value":"Not done","valueDescription":"Not Done","ValueMeaning":{"publicId":"2568055","version":"1","preferredName":"Not Done","longName":"2568055","preferredDefinition":"Indicates a task, process or examination that has either not been initiated or not been completed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Done","conceptCode":"C49484","definition":"Indicates a task, process or examination that has either not been initiated or not been completed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D6E4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-01-12","modifiedBy":"REEVESD","dateModified":"2014-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77DF90EA-4DAE-5840-E053-F662850AD41A","beginDate":"2018-10-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-10","modifiedBy":"ONEDATA","dateModified":"2018-10-10","deletedIndicator":"No"},{"value":"Not evaluated","valueDescription":"Unevaluable","ValueMeaning":{"publicId":"3855538","version":"1","preferredName":"Unevaluable","longName":"3855538","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3F3FD8B-328D-C859-E040-BB89AD43580F","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77DF90EA-4DB8-5840-E053-F662850AD41A","beginDate":"2018-10-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-10","modifiedBy":"ONEDATA","dateModified":"2018-10-10","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6002993","version":"1","preferredName":"Immune-related Response Evaluation Criteria In Solid Tumors Target Type","preferredDefinition":"A set of criteria for capturing the unidimensional measurements which are used to assess the effect of immunotherapeutic agents on solid tumors. These criteria are based on elements of the Immune-Related Response Criteria (irRC) and Immune-related RECIST (irRECIST).:An object fixed as a goal or point of examination; something to point at; a destination.:Something distinguishable as an identifiable class based on common qualities.","longName":"C140313:C25702:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune-related Response Evaluation Criteria In Solid Tumors","conceptCode":"C140313","definition":"A set of criteria for capturing the unidimensional measurements which are used to assess the effect of immunotherapeutic agents on solid tumors based on elements of Immune-related RECIST (irRECIST).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Target","conceptCode":"C25702","definition":"An object fixed as a goal or point of examination; something to point at; a destination.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5F741C-FE65-08CB-E053-F662850AC130","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"irRECIST: Immune-related Response Evaluation Criteria in Solid Tumours (RECIST)-2013","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"6419F027-AD90-089A-E053-F662850A4BDA","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-01-31","modifiedBy":"KNABLEJ","dateModified":"2018-10-23","changeDescription":"10/23/18 jk chg reg status to Standard for RECIST defined PV list; do not add PVs without checking latest version of guideline. 10/22/18 jk chg reg status to Qualified.  10/10/18 tt added 2 PVs per FG recommendation. 1/31/18 jk versioned to correct data type error, changed from number to character and min length to 4.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6921971","version":"1","longName":"CDISC Aligned Collection CDEs","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6921972","version":"1","longName":"RECIST - CDISC Aligned ","context":"NCI Standards"},{"publicId":"6921975","version":"1","longName":"irRECIST - CDISC Aligned","context":"NCI Standards"}]},{"publicId":"7434158","version":"1","longName":"CTEP CDISC Harmonization","context":"CTEP","ClassificationSchemeItems":[{"publicId":"7590131","version":"1","longName":"CTEP CDISC irRECIST","context":"CTEP"}]}],"AlternateNames":[{"name":"RS_RSORRES_TRGRESP_IRR","type":"CTEP CDISC CDE","context":"CTEP"}],"ReferenceDocuments":[{"name":"Target lesion","type":"Preferred Question Text","description":"Target lesion","url":null,"context":"NCI Standards"},{"name":"CTEP Text 1","type":"Alternate Question Text","description":"What is the target response?","url":null,"context":"CTEP"},{"name":"CTEP Text 2","type":"Alternate Question Text","description":"Target response","url":null,"context":"CTEP"}],"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"936B6754-F8B3-419D-E053-F662850A43AB","latestVersionIndicator":"Yes","beginDate":"2019-09-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-09-25","modifiedBy":"GDEEN","dateModified":"2023-02-13","changeDescription":"Released. AK 2020-8-31 Created for CDISC aligned NCI Standard CRF task. mc","administrativeNotes":"02.13.23_Set Reg Status to Standard for all CDISC Aligned content_ghd","unresolvedIssues":null,"deletedIndicator":"No"}}